Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in Radcliffe Department of Medicine have developed a heart ‘fingerprint’ to tailor personalised treatment for people at high risk of deadly heart attack.

© Shutterstock

Technology developed using artificial intelligence (AI) could identify people at high risk of a fatal heart attack at least five years before it strikes, according to new research funded by the British Heart Foundation (BHF). The findings are being presented at the European Society of Cardiology (ESC) Congress in Paris and published in the European Heart Journal.

Researchers at the University of Oxford have developed a new biomarker, or ‘fingerprint’, called the fat radiomic profile (FRP), using machine learning. The fingerprint detects biological red flags in the perivascular space lining blood vessels which supply blood to the heart. It identifies inflammation, scarring and changes to these blood vessels, which are all pointers to a future heart attack.

Read more (University of Oxford website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.